The Oncosearch | Oncotarget

Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy Research Paper

Benigno C. Valdez, Apostolia M. Tsimberidou, Bin Yuan, Yago Nieto, Mehmet A. Baysal, Abhijit Chakraborty, Clark R. Andersen, Borje S. Andersson

Published May 25, 2024 · Vol. 15, No. 1 · pp. 361-373

Keywords: decitabine, HDAC inhibitors, pancreatic cancer, PARP inhibitors, synergistic cytotoxicity

HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs Research Paper

Benigno C. Valdez, Yago Nieto, Bin Yuan, David Murray, Borje S. Andersson

Published Sep 24, 2022 · Vol. 13, No. 1 · pp. 1122-1135

Keywords: poly(ADP-ribosyl)ation, HDAC inhibitors, PARP inhibitors, chemotherapy, hematologic malignancy

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs Research Paper

Kelsey E. Huntington, Anna Louie, Lanlan Zhou, Wafik S. El-Deiry

Published Sep 11, 2021 · Vol. 12, No. 20 · pp. 1980-1991

Keywords: cytokine profiling, inflammatory response, chemokine, growth factor, immune profiling

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status Research Paper

Hélène Marijon, Sigal Gery, Hua Chang, Yosef Landesman, Sharon Shacham, Dhong Hyun Lee, Aimery de Gramont, Harold Phillip Koeffler

Published Aug 10, 2021 · Vol. 12, No. 18 · pp. 1749-1762

Keywords: selinexor, XPO1, olaparib, triple negative breast cancer, BRCA1

Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma Research Paper

Rami Mäkelä, Ville Härmä, Nibal Badra Fajardo, Greg Wells, Zoi Lygerou, Olle Sangfelt, Juha Kononen, Juha K. Rantala

Published May 6, 2021 · Vol. 12, No. 11 · pp. 1100-1109

Keywords: cutaneous apocrine sweat gland carcinoma, ex vivo drug screening, DNA repair, PALB2, rare cancer

Decreased expression of the translation factor eIF3e induces senescence in breast cancer cells via suppression of PARP1 and activation of mTORC1 Research Paper

Christelle Morris, Sébastien Durand, Pierre Jalinot

Published Mar 13, 2021 · Vol. 12, No. 7 · pp. 649-664

Keywords: breast cancer, senescence-associated secretory phenotype, eIF3, PARP1, mTORC1

Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line Research Paper

Masaki Kobayashi, Yuka Ishizaki, Mika Owaki, Yoko Matsumoto, Yuri Kakiyama, Shunsuke Hoshino, Ryoma Tagawa, Yuka Sudo, Naoyuki Okita, Kazunori Akimoto, Yoshikazu Higami

Published Apr 22, 2020 · Vol. 11, No. 18 · pp. 1653-1665

Keywords: nutlin-3a, PARP1, breast cancer, proteasomal degradation, autoPARylation

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model Correction

Gerben R. Borst, Ramya Kumareswaran, Hatice Yücel, Seyda Telli, Trevor Do, Trevor McKee, Gaetano Zafarana, Jos Jonkers, Marcel Verheij, Mark J. O’Connor, Sven Rottenberg, Robert G. Bristow

Published Jan 28, 2020 · Vol. 11, No. 17 · pp. 1573-1574

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer Research Paper

Irem Durmaz Sahin, Jenny-Maria Jönsson, Ingrid Hedenfalk

Published Dec 10, 2019 · Vol. 10, No. 65 · pp. 6981-6996

Keywords: HGSOC, c-Met, PARP inhibitor, apoptosis

MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma Priority Research Paper

David King, Xiao Dun Li, Gilberto S. Almeida, Colin Kwok, Polly Gravells, Daniel Harrison, Saoirse Burke, Albert Hallsworth, Yann Jamin, Sally George, Simon P. Robinson, Christopher J. Lord, Evon Poon, Daniel Yeomanson, Louis Chesler, Helen E. Bryant

Published Nov 6, 2019 · Vol. 11, No. 23 · pp. 2141-2159

Keywords: PARP inhibitor, neuroblastoma, MYCN, replication stress, replication fork stalling

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk Research Paper

Erika J. Lampert, John L. Hays, Elise C. Kohn, Christina M. Annunziata, Lori Minasian, Minshu Yu, Nicolas Gordon, Tristan M. Sissung, Victoria L. Chiou, William D. Figg, Nicole Houston, Jung-Min Lee

Published Apr 23, 2019 · Vol. 10, No. 30 · pp. 2855-2868

Keywords: high-grade serous ovarian cancer, BRCA wild type, olaparib, carboplatin

Computational analysis of data from a genome-wide screening identifies new PARP1 functional interactors as potential therapeutic targets Research Paper

Samuele Lodovichi, Alberto Mercatanti, Tiziana Cervelli, Alvaro Galli

Published Apr 12, 2019 · Vol. 10, No. 28 · pp. 2722-2737

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours Research Paper

Liliana D. Ordonez, Trevor Hay, Robert McEwen, Urszula M. Polanska, Adina Hughes, Oona Delpuech, Elaine Cadogan, Steve Powell, Jonathan Dry, Giusy Tornillo, Lucy Silcock, Elisabetta Leo, Mark J. O’Connor, Alan R. Clarke, Matthew J. Smalley

Published Apr 5, 2019 · Vol. 10, No. 27 · pp. 2586-2606

Keywords: PARP inhibitors, olaparib, Brca2, EMT, P-gps

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-Mutant mammary tumours Research Paper

Liliana D. Ordonez, Trevor Hay, Robert McEwen, Urszula M. Polanska, Adina Hughes, Oona Delpuech, Elaine Cadogan, Steve Powell, Jonathan Dry, Giusy Tornillo, Lucy Silcock, Elisabetta Leo, Mark J. O’Connor, Alan R. Clarke, Matthew J. Smalley

Published Mar 27, 2019

Keywords: PARP inhibitors, olaparib, Brca2, EMT, P-gps

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-Mutant mammary tumours Research Paper

Liliana D. Ordonez, Trevor Hay, Robert McEwen, Urszula M. Polanska, Adina Hughes, Oona Delpuech, Elaine Cadogan, Steve Powell, Jonathan Dry, Giusy Tornillo, Lucy Silcock, Elisabetta Leo, Mark J. O’Connor, Alan R. Clarke, Matthew J. Smalley

Published Mar 27, 2019

Keywords: PARP inhibitors, olaparib, Brca2, EMT, P-gps

Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy Research Paper

Tomoki Yamano, Shuji Kubo, Aya Yano, Tomoko Kominato, Shino Tanaka, Masataka Ikeda, Naohiro Tomita

Published Jan 8, 2019 · Vol. 10, No. 3 · pp. 352-367

PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation Research Paper

Greg Ngo, Sam Hyatt, Julia Grimstead, Rhiannon Jones, Eric Hendrickson, Chris Pepper, Duncan Baird

Published Dec 25, 2018 · Vol. 9, No. 101 · pp. 37549-37563

Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment Research Paper

Abdul Khalid Siraj, Poyil Pratheeshkumar, Sandeep Kumar Parvathareddy, Sasidharan Padmaja Divya, Fouad Al-Dayel, Asma Tulbah, Dahish Ajarim, Khawla S. Al-Kuraya

Published Dec 18, 2018 · Vol. 9, No. 99 · pp. 37319-37332

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models Research Paper

Kaiming Sun, Keith Mikule, Zebin Wang, Grace Poon, Aparajitha Vaidyanathan, Gillian Smith, Zhi-Yi Zhang, Jeffrey Hanke, Sridhar Ramaswamy, Jing Wang

Published Dec 14, 2018 · Vol. 9, No. 98 · pp. 37080-37096

Correction: Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells Correction

Vojtech Novohradsky, Juraj Zajac, Oldrich Vrana, Jana Kasparkova, Viktor Brabec

Published Oct 30, 2018 · Vol. 9, No. 85 · pp. 35599-35599

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy Research Paper

HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs Research Paper

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs Research Paper

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status Research Paper

Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma Research Paper

Decreased expression of the translation factor eIF3e induces senescence in breast cancer cells via suppression of PARP1 and activation of mTORC1 Research Paper

Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line Research Paper

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model Correction

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer Research Paper

MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma Priority Research Paper

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk Research Paper

Computational analysis of data from a genome-wide screening identifies new PARP1 functional interactors as potential therapeutic targets Research Paper

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours Research Paper

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-Mutant mammary tumours Research Paper

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-Mutant mammary tumours Research Paper

Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy Research Paper

PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation Research Paper

Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment Research Paper

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models Research Paper

Correction: Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells Correction

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy Research Paper

HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs Research Paper

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs Research Paper

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status Research Paper

Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma Research Paper

Decreased expression of the translation factor eIF3e induces senescence in breast cancer cells via suppression of PARP1 and activation of mTORC1 Research Paper

Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line Research Paper

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model Correction

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer Research Paper

MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma Priority Research Paper

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk Research Paper

Computational analysis of data from a genome-wide screening identifies new PARP1 functional interactors as potential therapeutic targets Research Paper

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours Research Paper

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-Mutant mammary tumours Research Paper

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-Mutant mammary tumours Research Paper

Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy Research Paper

PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation Research Paper

Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment Research Paper

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models Research Paper

Correction: Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells Correction